InsiderTrades.com logo
The Long-Awaited End of America Update
From Stansberry Research   |   Ad
A 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.
Click here to find out for free.
Adam D. George net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Adam George Biography and Net Worth

Insider of GW Pharmaceuticals
Adam George serves as Non-Executive Independent Director of the Company. He has been the UK Managing Director of GW Pharmaceuticals since March 2017 and also serves as GW Pharmaceuticals’ Company Secretary. GW Pharmaceuticals is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. Previously, Mr. George was GW Pharmaceutical's Chief Financial Officer from 2012 until March 2017 and Financial Controller from 2007 to 2012. Before joining GW Pharmaceuticals, Mr. George held several senior finance roles within both public and private companies. Mr. George holds a BSc. in Biology from Bristol University and is a Chartered Accountant.

What is Adam D. George's net worth?

The estimated net worth of Adam D. George is at least $7.57 million as of January 22nd, 2021. Mr. George owns 34,588 shares of GW Pharmaceuticals stock worth more than $7,573,388 as of May 3rd. This net worth estimate does not reflect any other investments that Mr. George may own. Learn More about Adam D. George's net worth.

How do I contact Adam D. George?

The corporate mailing address for Mr. George and other GW Pharmaceuticals executives is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. GW Pharmaceuticals can also be reached via phone at 44-12-2326-6800 and via email at [email protected]. Learn More on Adam D. George's contact information.

Has Adam D. George been buying or selling shares of GW Pharmaceuticals?

Adam D. George has not been actively trading shares of GW Pharmaceuticals during the last ninety days. Most recently, Adam D. George sold 14,700 shares of the business's stock in a transaction on Friday, January 22nd. The shares were sold at an average price of $11.69, for a transaction totalling $171,843.00. Following the completion of the sale, the insider now directly owns 34,588 shares of the company's stock, valued at $404,333.72. Learn More on Adam D. George's trading history.

Who are GW Pharmaceuticals' active insiders?

GW Pharmaceuticals' insider roster includes Cabot Brown (Director), Adam George (Insider), Justin Gover (CEO), Geoffrey Guy (Chairman), Volker Knappertz (Director), Douglas Snyder (Insider), and Christopher Tovey (COO). Learn More on GW Pharmaceuticals' active insiders.

Adam D. George Insider Trading History at GW Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2021Sell14,700$11.69$171,843.0034,588View SEC Filing Icon  
1/15/2021Sell79,860$11.73$936,757.8035,716View SEC Filing Icon  
1/13/2021Sell675,744$11.03$7,453,456.3213,636View SEC Filing Icon  
5/7/2019Sell258,324$16.10$4,159,016.40268,324View SEC Filing Icon  
See Full Table

Adam D. George Buying and Selling Activity at GW Pharmaceuticals

This chart shows Adam D George's buying and selling at GW Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

GW Pharmaceuticals Company Overview

GW Pharmaceuticals logo
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $218.96
Low: $218.96
High: $218.96

50 Day Range

MA: $218.59
Low: $216.90
High: $219.28

2 Week Range

Now: $218.96
Low: $87.07
High: $219.57

Volume

N/A

Average Volume

899,771 shs

Market Capitalization

$6.86 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15
The Long-Awaited End of America Update
From Stansberry Research   |   Ad
A 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.
Click here to find out for free.